



Soluble Therapeutics gets more funding, working two major collaborations

BIRMINGHAM, Alabama – [Soluble Therapeutics Inc.](#) has a second cash infusion that will help the company continue its work in protein-based pharmaceuticals as well as pursue two major research collaborations with global and U.S. partners.

The company, which is based in Birmingham’s [Innovation Depot](#) incubator, said [Targeted Technology Fund II](#) in San Antonio provided the undisclosed amount of funding. The investment comes at a year after Soluble received a \$1 million grant from the [National Institutes of Health](#).

Soluble said in a release the new funding will be used towards the company’s new research collaborations with a global pharmaceutical contract manufacturing organization and one with a large U.S.-based pharmaceutical company, that could lead to exclusive licensing deals for Soluble’s HSC technology.

The technology has to do with formulations to enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings the transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics.

“This funding represents a vote of confidence in the work that Soluble Therapeutics is doing and will allow us to continue expanding upon our initial success,” Joseph Garner, chief executive of Soluble, said in a release. “We are very excited about the research collaborations kicking off in 2014 and further demonstrating the value of the HSC technology in the marketplace.”

http://www.al.com/business/index.ssf/2013/12/soluble_therapeutics_gets_more.html